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Purpose: Fluorescence-guided surgery (FGS) provides surgeons with new opportunities to improve real-
time cancer nodule detection and tumor margin visualization. Currently, the most important challenge in
this field is the development of fluorescent dyes that specifically target tumors. We developed, char-
acterized and evaluated SGM-101, an innovative antibody-dye conjugate in which the fluorochrome
BM104, which has an absorbance band centered at 700 nm, is coupled to a chimeric monoclonal anti-
body (mAb) against carcinoembryonic antigen (CEA).
Methods: The dye to mAb ratio, binding to CEA and photobleaching of SGM-101 were determined. FGS
was performed and results analyzed using different mouse models of human digestive tumors.
Results: SGM-101 allowed the detection of tumor nodules in three different colon cancer models: LS174T
human colorectal adenocarcinoma cell-induced peritoneal carcinomatosis (PC) and liver metastases, and
orthotopic grafts of HT29 human colorectal adenocarcinoma cells. In the PC model, submillimeter-sized
nodules were detected during SGM-101-based FGS and SGM-101 predictive positive values ranged from
99.04% to 90.24% for tumor nodules >10 mg and nodules <1 mg, respectively. Similarly, in the orthotopic
model of pancreatic cancer using BxPC3 (pancreas adenocarcinoma) cells, SGM-101 could clearly
delineate tumors in vivo with a tumor-to-background ratio of 3.5, and penetrated in tumor nodules, as
demonstrated by histological analysis. Free BM105 dye (BM104 with an activated ester for conjugation to
the antibody) and an irrelevant conjugate did not induce any NIR fluorescence.
Conclusion: These preclinical data indicate that SGM-101 is an attractive candidate for FGS of CEA-
expressing tumors and is currently assessed in clinical trials.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).b, monoclonal antibody; IPD,
guided surgery; NIR, near




Ltd. This is an open access article u1. Introduction
Digestive cancers are the most frequent and deadly tumors in
both men and women (304 000 new cases and 153 000 deaths
estimated for 2016 in the USA) [1]. Among them, colorectal cancer
is the third most common cancer and leading cause of death in the
USA [1]. In approximately 15% of patients with colorectal cancer,
peritoneal carcinomatosis is already present at the time of diag-
nosis, and in 40% of patients, the disease is estimated to progress to
peritoneal metastases after the initial diagnosis [2,3]. The extent ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tivity and specificity of the current diagnostic tools (CT, MRI) in
detecting small-size tumor nodules [4]. Currently, the most reliable
diagnosis is obtained by direct observation through laparotomy or
laparoscopy.
Until recently, peritoneal carcinomatosis was considered a ter-
minal condition by most oncologists due to its very poor prognosis
and was treated only with palliative care. In recent years, Sugar-
baker et al. have introduced a new therapeutic approach that
combines cytoreductive surgery, to remove all visible tumor de-
posits from the peritoneal surface, and hyperthermic intraperito-
neal chemoperfusion, to target the microscopic residual disease
[5,6]. This treatment strategy has drastically improved the pri-
mary and secondary prognosis of peritoneal carcinomatosis. The
degree of macroscopic tumor resection is recorded using the
completeness of cytoreduction (CCR) score (CCR-0 corresponds to
absence of residual macroscopic peritoneal disease). Attaining a
CCR-0 resection can significantly improve the 5-year survival rates
of patients with colorectal cancer [7]. Therefore, powerful intra-
operative imaging techniques are urgently needed to help
achieving CCR-0 resection and for the accurate evaluation of tumor
extension [8].
Pancreatic cancer is less frequent (around 53 000 new cases
expected in the USA in 2016), but its mortality rate is very close to
the incidence rate (42 000 expected deaths) [1]. New techniques to
improve the current surgery outcomes should be developed,
particularly to avoid positive resection margins that occur in 30% of
patients [9].
Fluorescence imaging could provide surgeons with solutions to
improve tumor resection thanks to the recent development of
fluorescence-guided surgery (FGS) (see Refs. [10] and [11] for re-
view). FGS becomes feasible because there are now several
commercially available fluorescence image-guided surgery camera
systems [11]. However, the currently approved dyes (fluorescein,
methylene blue, ICG, IRD800CW) are non-targeted and/or are not in
the near infrared (NIR) range, which is the optimum for in vivo
applications [12]. High-performance NIR fluorescent targeted
agents are required to provide surgeons with optimal guidance
[13]. Monoclonal antibodies (mAbs) appear to be the best option to
target NIR dyes [14]. Although it took more than twenty years to
move from mice [15,16] to men and from pioneers' clinical work
[17] to clinical studies, the translation of immunophotodetection
(IPD; i.e., the use of dyes covalently linked to specific mAbs for the
intra-operative detection of tumors) into the clinic seems now very
close [18e21].
In the present study and as a first step toward clinical applica-
tions, we present the development and characterization of SGM-
101, an innovative NIR reagent in which an original dye, BM104,
is coupled to an anti-carcinoembryonic antigen (CEA) chimerized
mAb. The good results obtained in different murine models of
digestive cancers (orthotopic tumors, peritoneal carcinomatosis
and hepatic metastases) and the results of extensive toxicological
studies warrant a rapid clinical translation.
2. Materials and methods
2.1. Preparation and characterization of SGM-101 and control
antibody-dye conjugates
The anti-CEA chimeric mAb SGM-ch511was produced on a large
scale (0.8 g/l) using a clinical compatible subclone of the CHO
Protein-Free cell line (European Collection of Authenticated Cell
Cultures, cat number 00102307) derived at Vivalis, France. Aliquots
of 1 mg of SGM-ch511 in phosphate/bicarbonate buffer pH 9.3 were
mixed with BM105 (BM104 with an activated ester for conjugationto the antibody) or Alexa-Fluor 680 (AF680) dissolved in dime-
thylformamide (final concentration: 2.25 mg/ml) or with
IRDye800-CW in bicarbonate buffer pH 8.5, at the indicated initial
molar ratio. After agitation at 50 rpm at room temperature in the
dark for 45 min, the dye-mAb conjugates were separated from free
dye on PD-10 columns (GE Healthcare) equilibrated in elution
buffer (10 mM KH2PO4, 10 mM Na3Citrate, 300 mM Arginine, 0.02%
(w/w) Tween-20, pH 6.0). The dye/mAb molar ratios were calcu-
lated using the mAb and dye molarities determined from optical
density (OD) reading at 280 nm, 680 nm and 800 nm for AF680
(ε¼ 183 000 cm1.M1) and IRDye800-CW (ε¼ 240 000 cm1.M1)
conjugates, respectively. For BM105 conjugates, the samples'
absorbance was measured at 280 and 685 nm using a spectro-
photometer (Jenway 7315, Bibby Scientific France) and then the
labeling ratios were calculated using the following formula: Dye/
protein ¼ (Mdye)/((A280/(0.3  εprotein)/MWprotein)), where the
molar extinction coefficient of the protein (εprotein) was
1.5 M1 cm1, the molecular weight of the protein (MWprotein) was
150 000 g mol1. The molarity of the dye (Mdye) was calculated
using the following formula: Mdye ¼ (A685conjugate  10)/A685dye,
where A685conjugate was the absorbance of the conjugate at 685 nm
and A685dye was the absorbance of 10 mg of BM104 (diluted in the
same buffer as the conjugate) at 685 nm.
A competitive ELISA was used to determine the CEA epitope
recognized by SGM-ch511. Wells of a microtiter plate were coated
with 1 mg/well recombinant CEA (Abcam) in PBS at 22 C overnight.
After washing with PBS and saturationwith BSA 10 mg/ml in PBS, a
fix quantity of SGM-ch511 (2.5 ng/well) mixed with dilutions
(10 mg/ml to 1 ng/ml) of the reference mouse mAbs against the CEA
epitopes Gold 1 to 5 (B93, 35A7, B17, CE25, and 192, respectively
[22]) or the parental mAb 511was added to thewells and incubated
at 37 C for 2 h. After washings, SGM-ch511 binding to CEA was
revealed using peroxidase-labeled goat anti-human IgG and o-
phenylenediamine dihydrochloride (OPD) followed by reading at
490 nm.
Quantum yield (QY) was measured according to Würth C et al.
[23] using 5 mM of SGM-101, control conjugates and free dyes. After
absorbance and fluorescence measurements, QY was calculated
using the formula: fx ¼ fs (Fx/Fs) x (fs/fx) x (n2x/n2s), where fx was
the sample QY, fs was the standard QY (¼ 0.39 for Alexa Fluor® 680
in PBS), Fx was the integrated intensity of fluorescence of the
sample, Fs was the integrated intensity of fluorescence of the
standard, fs the absorption factor of the standard (¼110Absorbance
value), fx the absorption factor of the sample (¼110Absorbance value),
nx the refractive index of the sample buffer (e.g., n ¼ 1.4305 for
DMF, n ¼ 1.334 for PBS) and ns was the refractive index of the
standard buffer (1.334 for PBS).
Photobleaching of the different conjugates (diluted to the same
concentration) was measured after exposure to clinical wave-
lengths (i.e.wavelengths of the different devices approved for FGS).
After exposure, fluorescence emission was registered with a
spectrofluorimeter.
SGM-101 was radiolabeled with 2.5 mCi/mg 125I by using the
iodogen method (Pierce, Rockford, IL). Free 125I was separated from
labeled SGM-101 through a PD-10 column (GE Healthcare) equili-
brated in PBS. The specific activity of the radiolabeled conjugate
ranged from 1 to 2 mCi/mg. For binding analysis, 20 ng of 125I-SGM-
101 was mixed with CEA or an irrelevant antigen coupled to
Sepharose beads and incubated at 37 C with agitation overnight.
The binding ratio was calculated using the following equation: cpm
of the bound fraction (after bead washing)/cpm of the total fraction
(before bead washing).
Mass spectrometry was performed using a 4800 Maldi TOF/TOF
Analyzer (AB Sciex) and the 4000 Series Explorer™ software (AB
Sciex). After dialysis against PBS just before analysis, diluted
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acetronitrile, v/v) were loaded on the plate. Analysis was performed
using the “High mass linear” method in positive mode, with an
accelerating tension at source of 20 kV and aminimal accumulation
of 3000 shootings/spectrum. Four measurements for each sample
were carried out. The relative composition of the SGM-101 solution
(antibody coupled to several dye molecules) was obtained by
deconvolution of the main peak (corresponding to the sum of
unique spectra) and by comparison with the reference peak ob-
tained with the naked antibody.
The binding affinities of antibodies and conjugates for CEAwere
measured by surface plasmon resonance (SPR) using the BIACORE®
technology (GE Healthcare). CEA was covalently immobilized on a
CM5 sensor chip through thiol ligation, as recommended by the
manufacturer (Surface Thiol Coupling GE Healthcare Instruction
22-0618-10AB). A control reference surface (flowcell Fc1), prepared
using the same chemical treatment but without CEA injection, was
used to measure the background signal. Five increasing concen-
trations (1.5e50 nM) of the parental mouse mAb 511, chimeric
SGM-ch511 mAb and SGM-101 were used to determine the kinetic
parameters and calculate the affinity constants.
2.2. Cell lines and nude mouse tumor models
The BxPC-3 (pancreas adenocarcinoma), LS-174T and HT29
(colorectal adenocarcinoma) human cell lines (ATCC) were cultured
in RPMI-1640 mediumwith 10% fetal bovine serum in a humidified
incubator at 37 C and 5% CO2. The BxPC-3-luc2 cell-line was pur-
chased from PerkinElmer (MA, USA).
All animal experiments were performed in compliance with the
French government guidelines and the Institut National de la Sante
et de la Recherche Medicale regulations for experimental animal
studies (agreement B34-172-27), or the ‘‘Code of Practice for the
Use of Laboratory Animals in Cancer Research’’ (Inspectie W&V,
July 1999, The Netherlands) with the approval of the relevant ethics
committees in Montpellier, France, or Leiden, Netherlands. For tu-
mor cell inoculation and image acquisition, animals were anes-
thetized with 4% isoflurane for induction and 2% isoflurane for
maintenance.
Peritoneal carcinomatosis was induced by i.p. injection of 2.106
LS174T cells in 150 ml serum-free culture medium in NMRI nude
mice (Janvier, St Berthevin, France), as previously described [24].
Liver metastases were produced by intrasplenic injection of 5.105
LS174T cells in 50 ml serum-free culture medium through a 26-
gauge needle, as described [25]. For the orthotopic colon cancer
model, small fragments of subcutaneously growing HT29 tumors
were transplanted in the cecum of nude mice, as described [26]. To
induce subcutaneous tumors, BxPC-3 cells were injected at four
sites on the back (500 000 cells per spot) [26]. Orthotopic
pancreatic tumors were obtained as previously described by Kim
et al. [27]. Following image acquisition, tumors were quickly frozen
in isopentane for histological evaluation. Tumor growth in the
orthotopic models was monitored weekly by bioluminescence
imaging using luciferase-transfected cell lines, as previously
described [26].
2.3. In vivo tumor localization of radiolabeled mAb-dye conjugates
Thirty mg of 125I-SGM-101 were injected i.v. in nude mice with
LS174T cell-derived peritoneal carcinomatosis. 125I-SGM-101 up-
take in the thyroid was limited by adding 0.05% iodine solution
(Lugol) in the drinking water. To determine SGM-101 bio-
distribution kinetics, groups of five mice were killed and dissected
at different times (24 h, 48 h, 72 h and 96 h) after injection. The
tumors and all organs were weighed and their 125I radioactivitymeasured using a gamma counter. Results were expressed as per-
centage of the injected dose (ID) per gram of tissue (%ID/g).
Whole-body SPECT images were acquired at 24 h, 48 h, 72 h and
96 h post-injection using a SPECT/CT imager (NanoSpect/CT, Bio-
scan®). Mice were placed in prone position and scanned under
anesthesia (1 l/min gas flow and 2% isoflurane in air). Helical CT
scanning (45-keV) was followed by SPECT image acquisition (24
projections and 100s per projection). Imaging data were recon-
structed iteratively with InVivoScope® and HiSPECT® for CT and
SPECT, respectively.
2.4. NIR fluorescent imaging systems
Real-time NIR-fluorescence measurements and fluorescence-
guided resections were performed using the FLARE™ NIR imag-
ing system [26] or the V2IP system [28]. The Pearl Impulse small
animal imaging system (LICOR, Bad Homburg, Germany) was used
as an in vivo preclinical reference system to measure NIR fluores-
cent signals for biodistribution analysis and to calculate the tumor
to background ratios (TBRs). Specific and control images were
normalized and regions of interest were marked. The background
signals were extracted from the surrounding tissue that was
defined as the (normal) tissue/organ that lies around a tumor. After
measuring the signal intensity of the macroscopic images, the TBR
was calculated using the following formula: TBR ¼ mean signal
tumor/mean signal surrounding tissue.
2.5. Histological analysis
In the peritoneal carcinomatosis model, all biopsies and
dissected tumor tissues were histologically analyzed after
hematoxylin-eosin staining to determine the presence of tumor
cells and to calculate the FGS performance parameters. For
immunofluorescence analysis, imaging of 6-mm thick frozen tissue
sections was performed using an Odyssey NIR scanner.
2.6. Statistical analysis
The histological results were compared with the fluorescence
imaging data and reported in contingency tables. Sensitivity,
specificity, and positive and negative predictive values (PPV and
NPV) were then calculated [24]. Confidence limits were calculated
from the binomial distribution.
3. Results
3.1. SGM-101 preparation and characterization
The innovative SGM-101 antibody-targeted fluorescent contrast
agent is composed of two original molecules: the anti-CEA SGM-
ch511 chimeric mAb and the fluorescent dye BM105 (the BM104
dye with an activated ester for conjugation to the antibody; see
below for complete description) (Fig. 1A).
The mAb SGM-ch511 is the chimeric version of the mouse mAb
511 against the Gold 2 epitope of CEA [22]. Using five mAbs against
the five Gold epitopes andmAb 511 in a competitive ELISA assay, we
demonstrated that SGM-ch511 recognizes the same Gold epitope as
the anti-Gold 2 mAb (Fig. 1B). SGM-ch511 affinity for CEA
(3.27 1011 M) remained very close to that of the parental murine
mAb 511 (3.82  1011 M) and was not significantly modified upon
labeling with BM105 (3.21  1011 M), as indicated by the SPR re-
sults using a CEA-coated chip.
To determine the best BM104/mAbmolar ratio, eight conjugates
were synthetized with an initial molar ratio between 3 and 20,
which gave a final molar ratio between 1 and 4.5, respectively
Fig. 1. BM105 and SGM-101 characterization. A: Extended formula of the BM105 dye; B: Competitive ELISA assay showing that the binding of the chimeric antibody SGM-ch511 to
CEA is inhibited by its parental murine mAb 511 (:) and a reference mAb directed against the Gold 2 CEA epitope (✕), but not by reference mAbs against the Gold 1 (-), 3 (C), 4
(A) and 5 () CEA epitopes; C: Final conjugation ratios (curve) of BM104-SGM-ch511 conjugates, depending on the initial molar ratio, and their binding percentage to CEA (gray
bars) and to an irrelevant antigen (striped bars); D: Mass spectroscopy analysis of three SGM-101 batches to determine the percentage of each form; E: Photobleaching mea-
surement of SGM-101 (C), SGM-ch511-AF680 (:) and SGM-ch511-IRDye800-CW (-).
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higher than 90%, when the conjugate contained up to three BM104
molecules per mAb molecule. With higher dye loads, the specific
binding to CEA decreased and the non-specific binding (to the
irrelevant Ag) increased (Fig. 1C). Therefore, a final dye to mAb
molar ratio between 1 and 2 was chosen for all other experiments.
The average final dye to mAb molar ratio was determined using
absorption at 280 nm and 685 nm. A more precise analysis using
mass spectrometry provided the exact percentage of each form in
the final product (Fig. 1D). For example, a SGM-101 batch with an
average dye/mAb ratio of 1.6 included 31, 21, 46 and 2% of conjugate
with a dye/mAb ratio of 0, 1, 2 and 4, respectively (Fig. 1D). In
comparison, a conjugate with an average dye/mAb ratio of 1.1
contained 43% of SGM-101 with a 1/1 ratio, whereas a conjugate
with an average dye/mAb ratio of 2.2 contained about one third of
SGM-101 with three BM104 molecules per SGM-ch511 molecule.
The BM105 NIR dye is composed of BM104, a fluorescent car-
bocyanine dye with an activated ester that allows its conjugation to
the antibody (Fig. 1A). This fluorophore was specifically developed
to minimize the aggregation risk during the coupling reaction witha biological substrate and consequently to improve the optical and
labeling properties. BM105 absorbance peak was at 685 nm with a
good absorbance from 670 to 700 nm (about 70% of the 685 nm
maximum) and the fluorescence peak was at 705 nm. This allows
stimulation and detection using the “700 nm version” of the
available clinical devices (FLARE™ and Fluobeam; lex ¼ 660 and
680 nm, respectively; l for detection¼ 689e725 nm and > 700 nm,
respectively). The absorption and fluorescence of free BM105 and
antibody-linked BM104 were not significantly different (data not
shown). Based on the protocol provided by Würth C et al. [23], the
fluorescence QY of SGM-101 and of BM105 were measured and
compared to the QY of AF680 and IRDye800-CW, as free dyes or
conjugated with the SGM-ch511 mAb. AF680 was chosen because
its excitation wavelength is close to that of BM105 and IRDye800-
CW because it is the only dye which has been tested in clinical
trials [29]. BM105 QY values were 0.22 and 0.17 for the free and
conjugated forms, respectively. These values were very close to
those of AF680 (QY ¼ 0.42 and 0.33, free and conjugated forms,
respectively) and much higher than those of IRDye800-CW
(QY ¼ 0.05 and 0.02, free and conjugated forms, respectively).
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conjugates (Fig. 1E) showed that SGM-101 was very stable (67% and
31% of the initial fluorescence at 30 and 60min, respectively). SGM-
ch511-IRDye800-CW gave similar results, while SGM-ch511-AF680
was very unstable with only 22% of the initial fluorescence left at
15 min (Fig. 1E). In summary, when compared with SGM-ch511-
AF680 and SGM-ch511-IRDye800-CW, SGM-101 was the only
conjugate that associated high QYand low photobleaching up to 1 h
(a time period fully compatible with FGS).
3.2. SGM-101 for the detection of colon cancer peritoneal
carcinomatosis: biodistribution studies of 125I-SGM-101, SPECT-CT
imaging and immunophotodetection
SGM1-101 was first evaluated in a mouse model of peritoneal
carcinomatosis induced by i.p. injection of LS174T colorectalFig. 2. Biodistribution studies of 125I-SGM-101 in nude mice with LS174T cell-derived p
LS174T cell-derived peritoneal carcinomatosis at 24, 48, 72 and 96 h after i.v. injection of 30
in each organ. B: SPECT-CT images showing 125I-SGM-101 uptake by nodules in mice with L
planar, sagittal, frontal and transversal views.adenocarcinoma cells. To determine precisely SGM1-101 bio-
distribution, micewith peritoneal carcinomatosis were sacrificed at
different time points (24 he96 h) after i.v. injection of 30 mg 125I-
SGM-101 (Fig. 2A). Tumor uptake at 24 h post-injection was
14.35 ± 0.87% ID/g tumor and the maximal tumor uptake
(23.73 ± 5.42% ID/g) was reached at 48 h. Tumor uptake was still up
to 10.15 ± 4.76% ID/g tumor at 72 h. The tumor-to-normal tissue
ratios ranged from 2.40 ± 0.27, 3.89 ± 0.90, 2.81 ± 0.2 and
3.87 ± 0.89 for blood at 24, 48, 72 and 96 h, respectively, to
27.19 ± 3.70, 31.65 ± 4.03, 34.93 ± 7.41 and 36.96 ± 5.16 for muscle.
Intermediate values of 5.41 ± 0.68, 9.40 ± 3.11, 8.60 ± 2.14 and
9.54 ± 2.16 were observed in liver at the same time points after
injection. 125I-SGM-101 uptake in tumor nodules was also moni-
tored using SPECT-CT imaging (Fig. 2B).
Based on this biodistribution kinetics, FGS was performed in
eight mice with LS174T cell-induced peritoneal carcinomatosis 48 heritoneal carcinomatosis. A: Analysis of radioactivity distribution in nude mice with
mg of 125I-SGM-101. The % ID/g of tissue was determined by measuring the radioactivity
S174T cell-derived peritoneal carcinomatosis at 48 h after injection. From left to right:
Fig. 3. Immunophotodetection of tumor nodules in three mouse models of colon cancer. Animals were imaged under normal (color) or NIR light 48 h after i.v. injection of 30 mg
of SGM-101. A: LS174T cell-derived peritoneal carcinomatosis (V2IP imaging system); B: Orthotopic colon cancer model using HT29 cells (FLARE™ NIR imaging system); C: LS174T
cell-derived liver metastases obtained at day 22 (D22) and D30 after cell inoculation (V2IP imaging system).
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nodules ( > 10 mg), fluorescence could already be detected through
the skin before laparotomy (Fig. 3A). During laparotomy, a careful
analysis of the whole peritoneum allowed the resection of very
small tumor nodules that would not have been detected without
the antibody-targeted fluorescent dye (Fig. 3A).
In addition to the resection of all detectable fluorescent nodules,
biopsies of diaphragm, mesocolon, mesentery, omentum and
Douglas pouch were systematically performed. Their histological
analysis allowed calculating SGM-101-based FGS sensitivity, spec-
ificity, PPV and NPV (Table 1). Fluorescent nodules (n ¼ 312) were
divided in three groups according to their weight (  1 mg; > 1
and 10mg; 10mg) to analyze the influence of the tumor size on
FGS sensitivity (Table 1B). The tumor nature of all fluorescent
nodules > 10 mg, but one (99% PPV), was confirmed by histological
analysis. For nodules < 1 mg, PPV was still high (90.24%). These
results confirmed SGM-101 capacity to target very small (sub-
millimeter sized) tumor nodules and to make them detectable for
FGS.3.3. SGM101 allows the visualization of orthotopic colon cancer
grafts, liver metastases and pancreatic tumor cell xenografts
Besides peritoneal carcinomatosis of digestive cancers, SGM-101
could be an attractive fluorescent tracer for FGS of colorectal and
pancreatic carcinomas. SGM-101 performances were therefore
analyzed in orthotopic tumor models because they are closer to the
clinical situation than subcutaneous tumor cell grafts. The dose of
30 mg SGM-101 and the 48 h delay between injection and IPD were
kept constant in all these experiments. The results obtained in the
pancreatic cancer model will be described more in detail.
First, in the orthotopic colon cancer model using HT29 cells,
mice injected with SGM-101 showed a bright fluorescence nodule
that was clearly demarcated from the surrounding tissue (Fig. 3B).
The largest nodules were detectable before laparotomy. Second,
liver metastases could be detected about 3 weeks after intra-
splenic injection of LS174T colorectal adenocarcinoma cells
(Fig. 3C). Smaller than 1 mm3 nodules, which were undetectable by
visual inspection or palpation, were fluorescent and their tumorTable 1
FGS performance parameters in the LS174T cell-derived peritoneal carcinomatosis
model.
A. Fluorescent nodules and not fluorescent biopsies of diaphragm, mesocolon,











B: Results of histological analysis of fluorescent nodules subdivided according to
their weight
Nodule weight Presence of
tumor
PPV Confidence limits (95%)
Yes No
>10 mg 103 1 99.04 94.8e99.9
10 mg > nodule > 1 mg 162 5 97.01 93.1e99.0
<1 mg 37 4 90.24 76.9e97.3nature was confirmed by histological analysis (data not shown).
Larger LS174T cell nodules also were fluorescent (Fig. 3C). Third, the
orthotopic pancreatic cancer model using BxPC3-luc2 cells allowed
demonstrating that SGM-101-induced fluorescence co-localized
with luciferase-positive tumor cells (Fig. 4A). The need of a
tumor-specific conjugate was confirmed by comparing SGM-101
with an irrelevant conjugate (at the same dose as SGM-101,
30 mg) and with free BM105 (250 ng; this dose corresponds to
the quantity of BM105 contained in 30 mg of SGM-101). BM105 and
the irrelevant conjugate did not induce any tumor-associated
fluorescence (Fig. 4A). Using the FLARE™ imaging system, a TBR
of 3.5 ± 0.6 was calculated for SGM-101-injected mice, compared
with 1.2 ± 0.5 and 1.0 ± 0.1 for mice injected with BM105 or the
irrelevant conjugate, respectively (Fig. 4B). After imaging, ortho-
topic pancreatic tumors were excised and snap-frozen. Consecutive
pancreatic tumor tissue sections were imaged to evaluate the dis-
tribution of the fluorescent signal, or stained with hematoxylin and
eosin to confirm the presence of human tumor cells. The localiza-
tion of the fluorescent signal and of tumor cells was remarkably
similar (Fig. 4C).
4. Discussion
FGS is moving rapidly into the clinic and there is a consensus
between experts that the current limiting factor, particularly in
oncology, is the fluorescent agent [10,11,13,29]. Indeed, although
there is still some room for improvement, several optical devices
have been developed and marketed (e.g., QUEST medical imaging
and Fluoptics) thanks to the active research and development in
recent years [30,31]. Concerning targeting agents, fluorescent dyes
conjugated with specific mAbs can combine exquisite tumor
specificity and optimal fluorescence performances
[15e20,26,32,33]. Here, we describe SGM-101, an innovative con-
jugate that combines the specific tumor-targeting properties of an
anti-CEA mAb with an optimal fluorescent dye (BM104).
Thanks to the use of mAbs as therapeutic agents, all the issues
concerning their development, large production according to good
manufacturing practices and related costs have been already
overcome [34]. More precisely concerning SGM-101, the SGM-
ch511 mAb production yields were about 0.8e1 g/l at the clinical
grade in CHO and the conjugation process with BM105 was robust
enough to be performed with batches of several grams of mAb.
These good production conditions together with a planned low
injected dose (several mg, see below for details) should allow the
commercialization of SGM-101 at an affordable price. The most
important remaining question is the target antigen to be used in
FGS. For many years, radiolabeled anti-CEA antibodies have been
evaluated and used in the clinic for imaging and therapy. However,
up to now, their potential did not translate into marketed and
routinely used reagents [35e38]. CEA is one of the most relevant
target antigens for FGS because it is expressed in almost all diges-
tive cancers and in most breast cancers at high antigenic density
[39]. Its expression at the cell surface is stable and constant from
primary tumors to all types of metastases. For these reasons,
several groups are interested in evaluating anti-CEA/dye conjugates
to develop tools for FGS of digestive cancers [15e17,26,32,33]. For
other pathologies, some authors have been using already approved
therapeutic mAbs, despite their limited relevance for FGS [18e20].
Indeed, the antigens targeted by these mAbs are not widely
expressed (e.g., HER2 only in 30% of breast cancers) or not at the
membrane (e.g., VEGF), or they are also strongly expressed in
normal tissues (e.g., EGFR that also shows variable expression in
tumors). The high CEA antigenic density (105 to 106 antigens per
cell) in most cancers is an important success factor for FGS [40].
With such an antigenic density, one can expect to achieve a dye
Fig. 4. Immunophotodetection of tumors in a mouse orthotopic model of pancreatic cancer using BxPC3 cells. A: Animals with orthotopic BxPC3 cell-derived tumor xe-
nografts were sacrificed 48 h after i.v. injection of 250 ng of BM105 dye, 30 mg of non-specific (irrelevant) conjugate or 30 mg of SGM-101. Images were acquired using the Pearl
Impulse small animal imaging system for bioluminescent detection of tumor cells (Bioluminescence) and with the FLARE™ NIR imaging system for fluorescence visualization at
700 nm (NIR). B: The tumor to background ratio was calculated using the formula: TBR ¼ mean signal tumor/mean signal surrounding tissue using the signal intensity for each
tissue measured with the Pearl Impulse imaging system. C: Histologic and immunofluorescence analyses of BxPC3 cell-derived tumor xenografts showing that the fluorescence
signal is only observed in tumors from mice injected with SGM-101.
M. Gutowski et al. / Surgical Oncology 26 (2017) 153e162160concentration of up to 1 mMassuming a 1:1 ratio of targeted dye per
receptor ([10,41] and personal computations). This corresponds to
the maximal calculated concentration and the SGM-101 high af-
finity for CEA (3.21  1011 M) should make possible to be close to
it. The present study focused on digestive cancers; however, CEA is
expressed in 65% of breast cancers [42] and obtaining clear margins
is very important, especially during breast-sparing surgery [43].
Therefore, FGS using SGM-101 could be useful also in this setting.
When coupled to SGM-ch511, BM104 compared favorably with
AF680, a dyewith similar excitation and emissionwavelengths, and
with IRDye800-CW the only dye that can be coupled to mAbs and
has been used in clinical trials. SGM-101 was the only conjugate
with high QY and low photobleaching for a time period compatible
with FGS (Fig. 1). BM104 was centered on 700 nm (lex 685 nm, lem
705 nm) for several reasons: (i) at 700 nm, the maximum pene-
tration of light in live tissues (around 10 mm) is already achieved
[30]; (ii) at 700 nm, the quantum efficiency of the camera is higher
than at 800 nm where it can be  25% [13,31]; (iii) with a tumor-
targeting agent centered on 700 nm, a non-specific dye centeredon 800 nm, such as ICG, can be concomitantly used for analysis of
normal tissue functions or reconstructive surgery [44].
In imaging, there has been a tendency to use mAb fragments,
such as single-chain variable fragments (scFv) [26,45] or nano-
bodies [46,47], based on the argument that a short kinetics is more
favorable and that small entities can penetrate more deeply in tu-
mor nodules. Nevertheless, here we show by immunofluorescence
analysis of orthotopic BxPC3 tumors that SGM-101 can penetrate in
submillimeter-sized tumor nodules and give a homogeneous tumor
uptake (Fig. 4C). Moreover, the use of intact mAbs is fully
compatible with clinical constraints. Indeed, thanks to their longer
half-life (compared with antibody fragments), intraoperative im-
aging using dye-intact mAb conjugates can be performed during a
longer period of time after injection. For example, preliminary data
from an open clinical trial using cetuximab-IRDye 800CW show
that surgery can be performed within 2e5 days after injection
(NCT02736578). Finally, the core chemical compound that absorbs
and emits in the near-infrared is necessarily large and hydrophobic
[13]. By using intact mAbs, the potential hydrophobicity of the dye
M. Gutowski et al. / Surgical Oncology 26 (2017) 153e162 161has a limited effect on the conjugate hydrophilicity. In the present
work, we demonstrate that SGM-101, which contains an average of
1.6 BM104 molecules per mAb molecule, behaves like the uncon-
jugated SGM-ch511 mAb with no major accumulation in normal
tissues. Conversely, when using an anti-CEA disulfide-stabilized
scFv coupled to IRDye800-CW (ssSM3E/800CW), accumulation also
in liver and kidney was observed in the BxPC3 cell-derived ortho-
topic pancreatic cancer model [26]. In the same orthotopic
pancreatic tumor model, the maximal TBR was 3.5 ± 0.9 for SGM-
101 (Fig. 4C) and 2.37 ± 0.4 for ssSM3E/800CW [26] at 48 h and
24 h post-injection, respectively.
For SGM-101 clinical translation, some issues need to be solved,
particularly: (i) the administration route (i.v. vs topical) and, in the
case of i.v. injection, the delay between administration and surgery;
and (ii) the dose to be injected. Topical spraying is claimed to be the
simplest way to administer targeted agents for FGS [48]. However,
topically administered compounds can only highlight the struc-
tures at the surface of which they are applied. Conversely, injectable
drugs can highlight structures below the surface, thus directing the
surgeon to structures that they have not seen by naked eye [11]. We
and others [11] are convinced that this topographically unbiased
ability to highlight the structures of interest is superior for surgical
applications. When mAb-dye conjugates are used, the kinetic pa-
rameters also need to be considered because optimal antibody
binding to its cognate antigen is not immediate [49]. Here again, i.v.
injection is more favorable than topical administration. The injec-
ted dose and the interval between injection and surgery should
allow optimal binding and consequently a clear visualization of
tumor nodules without any significant background signal, due to
circulating conjugate. In our mouse model of peritoneal carcino-
matosis, the maximum tumor uptake was at 24 h (Fig. 2A). As mAb
kinetics are slower in humans, a larger time window, between 24 h
and 96 h, should be considered for FGS after i.v. injection.
The choice of dose to be used is not an easy task because FSG is a
multi-parametric approach and the results depend on the targeted
antigen, the fluorescent dye-mAb conjugate and the imaging device
performances. When using conventional strategies to convert ani-
mal doses to human-equivalent doses, such as those based on the
body surface area [50], the SGM-101 dose of 30 mg for a mouse
weighing 20 g corresponds to about 10 mg for a human patient of
80 kg. For mAb-targeted dyes, the dose could also be chosen on the
basis of previous imaging studies using radiolabeled antibodies.
Such approach gives doses in the same range as those obtained
based on the body surface area [37]. Such dose calculation depends
also on the target antigen. Only CEA expressed by the tumor nodule
can be accessed by i.v. injected mAbs because all CEA expressed on
the apical side of normal colon cannot be reached [37]. Based on
these different methods, doses between 5 and 15 mg should be
used in future clinical trials. With antibodies against more ubiqui-
tous antigens, such as EGFR, higher doses need to be used to
compensate for the uptake by normal organs (up to 62.5 mg/m2;
i.e., more than 100 mg per injection in the first clinical trial of
cetuximab-IRDye800 in head and neck cancers [51]).
Based on the present preclinical data using different mouse
models of digestive cancers, extensive regulatory toxicological
studies were performed and confirmed that SGM-101 is safe for
human use (manuscript in preparation). Clinical trials are now in
progress in patients with digestive cancer peritoneal carcinoma-
tosis, pancreatic cancer or rectum cancer.
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